{
    "Trade/Device Name(s)": [
        "LIAISON Anti-HAV"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K193532",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082049"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JJE"
    ],
    "Summary Letter Date": "December 17, 2019",
    "Summary Letter Received Date": "December 20, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3310"
    ],
    "Regulation Name(s)": [
        "Hepatitis A Virus (HAV) Serological Assays"
    ],
    "Analyte Class(es)": [
        "serology",
        "virology"
    ],
    "Analyte(s)": [
        "Total antibodies to hepatitis A (anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON Analyzer family",
        "LIAISON XS Analyzer",
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive sandwich immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON Anti-HAV chemiluminescent immunoassay for qualitative detection of total antibodies to hepatitis A virus using LIAISON analyzers.",
    "Indications for Use Summary": "Qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma as an aid in diagnosing current or previous HAV infection and in determining antibody response to HAV in vaccine recipients; not for blood, solid, or soft tissue donor screening.",
    "fda_folder": "Microbiology"
}